Manchester, UK-based DxS announced last week the launch of its K-RAS Mutation Detection Kit.
The company, in a statement, cited recently published data that suggests that in lung cancer patients K-RAS mutation status is a strong predictor of resistance to therapy with tyrosine kinase inhibitors, such as AstraZeneca’s Iressa and Roche/OSI Pharmaceuticals’ Tarceva.
“The DxS K-RAS mutation detection kit can be used to identify these patients,” DxS said. “The kit will also be used to provide valuable biomarker information to drug companies with novel therapies in development.”
The real-time PCR-based kit detects seven key mutations in the K-RAS gene. The assays can detect less than 1 percent of mutations in wild type genomic DNA and have a limit of detection of 10 copies or below.
“The unparalleled sensitivity of the technology means that the kit detects mutations frequently missed by sequencing methods,” the company said.